Summary of SteadyMed Ltd. (NASDAQ:STDY) Ratings on Apr 20, 2018

April 20, 2018 - By Nellie Deboer

SteadyMed Ltd. (NASDAQ:STDY) Corporate Logo

SteadyMed Ltd. (NASDAQ:STDY) Ratings Coverage

In total 2 analysts cover Steadymed (NASDAQ:STDY). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 2 are the (NASDAQ:STDY)’s analyst reports since January 10, 2018 according to StockzIntelligence Inc. On Monday, April 9 H.C. Wainwright maintained SteadyMed Ltd. (NASDAQ:STDY) with “Buy” rating. Listed here are SteadyMed Ltd. (NASDAQ:STDY) PTs and latest ratings.

09/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $15.0000 Maintain
10/01/2018 Broker: JMP Securities Rating: Buy

$3.1 was the last price.Since April 20, 2017 it’s 15.19% down thus downtrending. The stock underperformed the S&P500 by 26.74%.

SteadyMed Ltd., together with its subsidiaries, operates as a specialty pharmaceutical firm that focuses on the development and commercialization of drug product candidates for the treatment of orphan and other diseases with unmet parenteral delivery needs.The firm is worth $82.38 million. The companyÂ’s product candidates are enabled by its proprietary PatchPump, a discreet, pre-filled, water-resistant, and disposable parenteral drug administration technology.Currently it has negative earnings. The Company’s lead drug product candidate is Trevyent, a development stage drug that combines PatchPump technology with treprostinil, a vasodilatory prostacyclin analogue for treating pulmonary arterial hypertension.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: